Talaris Therapeutics, Inc. Short Interest Up 29.9 percent in July

TALSDelisted Stock  USD 2.98  0.10  3.25%   
Slightly above 61% of Talaris Therapeutics' investor base is looking to short. The analysis of current outlook of investing in Talaris Therapeutics suggests that many traders are alarmed regarding Talaris Therapeutics' prospects. Talaris Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Talaris Therapeutics' earnings reports, geopolitical events, and overall market trends.
  
Talaris Therapeutics, Inc. was the recipient of a large growth in short interest during the month of July. As of July 31st, there was short interest totalling 314,500 shares, a growth of 29.9 percent from the July 15th total of 242,100 shares. Approximately 1.5 percent of the shares of the stock are

Read at thelincolnianonline.com
news
  

Talaris Therapeutics Fundamental Analysis

We analyze Talaris Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Talaris Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Talaris Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Working Capital

Working Capital Comparative Analysis

Talaris Therapeutics is currently under evaluation in working capital category among its peers. Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .

Talaris Therapeutics Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Talaris Therapeutics stock to make a market-neutral strategy. Peer analysis of Talaris Therapeutics could also be used in its relative valuation, which is a method of valuing Talaris Therapeutics by comparing valuation metrics with similar companies.

Peers

Talaris Therapeutics Related Equities

EWTXEdgewise Therapeutics   0.53   
5.0%
NXTCNextCure   1.11   
12.0%
ACHLAchilles Therapeutics   2.02   
22.0%
TILInstil Bio   3.60   
39.0%
SPROSpero Therapeutics   3.88   
42.0%
OVIDOvid Therapeutics   4.72   
51.0%
ASMBAssembly Biosciences   5.39   
58.0%
CTMXCytomX Therapeutics   6.19   
67.0%
ACETAdicet Bio   6.25   
68.0%
CGEMCullinan Oncology   6.27   
68.0%
NUVBNuvation Bio   7.12   
77.0%
CNTBConnect Biopharma   7.55   
82.0%
VORVor Biopharma   9.18   
100.0%
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.

Other Consideration for investing in Talaris Stock

If you are still planning to invest in Talaris Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Talaris Therapeutics' history and understand the potential risks before investing.
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Bonds Directory
Find actively traded corporate debentures issued by US companies
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account